[go: up one dir, main page]

HK1205928A1 - 一種眼部給藥系統 - Google Patents

一種眼部給藥系統 Download PDF

Info

Publication number
HK1205928A1
HK1205928A1 HK15104000.3A HK15104000A HK1205928A1 HK 1205928 A1 HK1205928 A1 HK 1205928A1 HK 15104000 A HK15104000 A HK 15104000A HK 1205928 A1 HK1205928 A1 HK 1205928A1
Authority
HK
Hong Kong
Prior art keywords
delivery system
drug delivery
composition
rhgh
ocular drug
Prior art date
Application number
HK15104000.3A
Other languages
English (en)
Inventor
Barbara Wirostko
Original Assignee
Jade Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jade Therapeutics, Llc filed Critical Jade Therapeutics, Llc
Publication of HK1205928A1 publication Critical patent/HK1205928A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15104000.3A 2012-04-16 2013-04-16 一種眼部給藥系統 HK1205928A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261624730P 2012-04-16 2012-04-16
US61/624,730 2012-04-16
US13/835,729 US20140107025A1 (en) 2012-04-16 2013-03-15 Ocular drug delivery system
US13/835,729 2013-03-15
PCT/US2013/036807 WO2013158661A1 (en) 2012-04-16 2013-04-16 Ocular drug delivery system

Publications (1)

Publication Number Publication Date
HK1205928A1 true HK1205928A1 (zh) 2015-12-31

Family

ID=49384009

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104000.3A HK1205928A1 (zh) 2012-04-16 2013-04-16 一種眼部給藥系統

Country Status (4)

Country Link
US (1) US20140107025A1 (zh)
EP (1) EP2838511B1 (zh)
HK (1) HK1205928A1 (zh)
WO (1) WO2013158661A1 (zh)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
JP5883539B2 (ja) 2012-03-16 2016-03-15 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｈｉｆ−１阻害剤の送達のための放出制御製剤
US10159743B2 (en) 2012-03-16 2018-12-25 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6360040B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9889208B2 (en) 2012-05-04 2018-02-13 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
EP2865421B1 (en) * 2013-10-28 2018-05-30 Albert-Ludwigs-Universität Freiburg Bitter taste receptor agonists for topical use
WO2015127389A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic enema formulations and methods of use
EP3122296B1 (en) * 2014-05-12 2018-10-17 CXL Ophthalmics, LLC Ophthalmic treatment solution delivery devices and delivery augmentation methods
EP3233058A1 (en) 2014-12-15 2017-10-25 The Johns Hopkins University Sunitinib formulations and methods for use thereof in treatment of glaucoma
US9937074B2 (en) 2015-01-22 2018-04-10 Eyegate Pharmaceuticals, Inc. Iontophoretic contact lens
KR20170106460A (ko) 2015-01-27 2017-09-20 더 존스 홉킨스 유니버시티 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US20180250292A1 (en) * 2015-09-04 2018-09-06 Indiana University Research And Technology Corporation Antibiotic gel formulation and methods of preparing the antibiotic gel formulation
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治療的聚集性微粒
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
EP3600441A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
EP4107166A4 (en) 2020-02-20 2024-06-26 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
EP4114392A4 (en) 2020-03-05 2024-04-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
IL298294A (en) 2020-05-19 2023-01-01 G1 Therapeutics Inc Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
WO2022066774A1 (en) 2020-09-23 2022-03-31 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2025080727A1 (en) * 2023-10-10 2025-04-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Autologous serum insert for treating an ocular condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090662A2 (en) * 2002-04-25 2003-11-06 Rapidheal, Inc. Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
US20100330143A1 (en) * 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
MX2009004856A (es) * 2006-11-09 2009-06-05 Alcon Res Ltd Matriz polimerica insoluble en agua para suministro de farmaco.
CN103619327A (zh) * 2010-12-29 2014-03-05 嘉德治疗股份有限公司 眼部给药体系

Also Published As

Publication number Publication date
EP2838511B1 (en) 2018-05-30
EP2838511A4 (en) 2015-12-09
WO2013158661A1 (en) 2013-10-24
US20140107025A1 (en) 2014-04-17
EP2838511A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
HK1205928A1 (zh) 一種眼部給藥系統
EP4303321A3 (en) Antisense oligomers for treatment of conditions and diseases
PH12017501910A1 (en) Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
WO2015106269A8 (en) Rapid action insulin formulations and pharmaceutical delivery systems
WO2012092510A3 (en) Ocular drug delivery system
WO2012129407A3 (en) Intraocular lens loading systems and methods of use
NZ701915A (en) High-concentration monoclonal antibody formulations
HK1198279A1 (zh) 用拉喹莫德與醋酸格拉替雷的組合治療多發性硬化症
WO2014012069A3 (en) Dry powder drug delivery systems and methods
WO2015017609A3 (en) Systems and methods for drug delivery, treatment, and monitoring
WO2011107750A3 (en) Delayed prolonged drug delivery
RU2739037C3 (ru) Композиция для контролируемой стимуляции яичников
HK1199820A1 (zh) 以拉喹莫德和芬戈莫德的組合治療多發性硬化症
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
BR112013027161A2 (pt) derivado reticulado de ácido hialurônico, processo de preparação do derivado, derivado reticulado de ácido hialurônico e uso do derivado reticulado
WO2013173417A3 (en) Glucokinase activator compositions for the treatment of diabetes
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
HK1198278A1 (zh) 用拉喹莫德與乾擾素-β的組合治療多發性硬化症
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
HK1203394A1 (zh) 用於治療胃酸缺乏的飢餓素受體激動劑
MX2022008220A (es) Extractos de planta con actividades antidiabeticas y otras.
EP4403220A3 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
JP2013504519A5 (zh)
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
IN2014KN02739A (zh)